N
CRBU icon

Nuveen’s Caribou Biosciences CRBU Stock Holding History

Nuveen’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-330,831
Closed -$302K – 3297
2025
Q1 		$302K Hold
330,831
– – ﹤0.01% 3043
2024
Q4 		$526K Buy
330,831
+63,096
+24% +$127K ﹤0.01% 2967
2024
Q3 		$525K Hold
267,735
– – ﹤0.01% 3002
2024
Q2 		$439K Hold
267,735
– – ﹤0.01% 3035
2024
Q1 		$1.38M Hold
267,735
– – ﹤0.01% 2564
2023
Q4 		$1.53M Buy
267,735
+18,695
+8% +$92.4K ﹤0.01% 2530
2023
Q3 		$1.19M Buy
249,040
+16,162
+7% +$100K ﹤0.01% 2505
2023
Q2 		$990K Sell
232,878
-60,086
-21% -$270K ﹤0.01% 2666
2023
Q1 		$1.56M Sell
292,964
-13,922
-5% -$86.7K ﹤0.01% 2435
2022
Q4 		$1.93M Buy
306,886
+83,479
+37% +$743K ﹤0.01% 2403
2022
Q3 		$2.36M Sell
223,407
-31,459
-12% -$293K ﹤0.01% 2317
2022
Q2 		$1.38M Buy
254,866
+62,686
+33% +$479K ﹤0.01% 2628
2022
Q1 		$1.76M Buy
192,180
+129,399
+206% +$1.36M ﹤0.01% 2560
2021
Q4 		$1.01M Sell
62,781
-3,007
-5% -$58.5K ﹤0.01% 2859
2021
Q3 		$1.57M Buy
+65,788
New +$1.61M ﹤0.01% 2788

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's CRBU Position: Q2 2025 in Review

Nuveen sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 330,831 shares — an estimated $302K sold.

Nuveen first reported a position in CRBU in Q3 2021 and held it in 15 quarters. The position peaked at $2.36M in Q3 2022. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • Nuveen reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 330,831 Caribou Biosciences shares in Q2 2025, an estimated $302K.
  • Nuveen first reported a position in Caribou Biosciences in Q3 2021 and held it in 15 quarters.
  • Nuveen's Caribou Biosciences position peaked at $2.36M in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.